跳至主要内容
临床试验/EUCTR2016-000891-54-SE
EUCTR2016-000891-54-SE进行中(未招募)1 期

Effects of enhanced dopaminergic neurotransmission on working memory training efficiency in the healthy elderly - A prospective, single center, randomized, double blind, placebo controlled, parallel group, phase II trial - REBOOT-II

Aging Research Center, Karolinska Institutet and Stockholm University0 个研究点目标入组 70 人开始时间: 2016年10月5日最近更新:
适应症
相关药物

试验速览

阶段
1 期
状态
进行中(未招募)
发起方
入组人数
70

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional clinical trial of medicinal product

入排标准

性别
All

入选标准

  • Mini-Mental State Examination score >26;
  • Aged between 65 and 75 years;
  • Absence of medical or psychiatric conditions specified in the exclusion criteria;
  • Signed informed consent;
  • Right handedness;
  • Fluent Swedish;
  • Absence of colorblindness;
  • No previous participation in studies of similar design;
  • No trauma to the head with loss of consciousness for more than 10 min;
  • No history of brain injuries;
  • No hormonal imbalance diseases (e.g. Cushing’s syndrome);
  • Are the trial subjects under 18? no
  • Number of subjects for this age range:
  • F.1.2 Adults (18-64 years) no
  • F.1.2.1 Number of subjects for this age range
  • F.1.3 Elderly (>=65 years) yes
  • F.1.3.1 Number of subjects for this age range 70

排除标准

  • Glaucoma (any history);
  • Any history of serious heart disease (myocardial infarction, arrhythmia, atrioventricular block);
  • Serious problems with heart and blood vessels, systolic/diastolic blood pressure < 100/50 or >160/95; Heart Failure: NYHA > IB; Chronic Venous Disease CEAP > C2);
  • Severe pulmonary diseases;
  • Type I diabetes;
  • Recent history (5 years) of stomach and duodenum ulcers;
  • Liver diseases (e.g. hepatitis, liver failure);
  • Bleeding of the stomach or intestines;
  • Kidney diseases;
  • Serious urination problems;
  • Recent history (5 years) of malignant tumor or mole, melanoma;
  • Major psychiatric disorders such as major depression, bipolar affective disorder, psychosis (risks of exacerbation of psychiatric symptoms). History of mild to moderate depression/anxiety is allowed (but not recent: 5 year cut-off);
  • Patients with neurological (Parkinson's and other movement disorders, Alzheimer's disease, epilepsy) disorders will also be excluded, as the present project targets healthy elderly population;
  • MRI contra-indications: metal body implants and pacemakers, cochlear implants, claustrophobia, weight over 120 kg;
  • Hypersensitivity to pro-dopaminergic drugs;
  • Hypersensitivity to citrus fruits/ascorbic acid;

研究者

发起方
Aging Research Center, Karolinska Institutet and Stockholm University

相似试验

已完成
4 期
Pharmaceutical enhancement of complex problem-solving in healthy adultsCognitive enhancementMental Health - Studies of normal psychology, cognitive function and behaviourNeurological - Studies of the normal brain and nervous system
ACTRN12617001544369The University of Melbourne32
已完成
不适用
The effects of increased levels of dopamine on the activation in the dopaminergic system.n.v.t.10009841
NL-OMON33408niversiteit Maastricht20
招募中
2 期
The effect of dopamine on the appropriate time of urination in oliguric patientsoliguria.Anuria and oliguria
IRCT2017011513366N6Vice Chancellor for Research,Arak University of Medical Sciences120
进行中(未招募)
1 期
Effet de la stimulation dopaminergique continue par pompe à apomorphine sur les fluctuations cognitives et psychiques des patients parkinsoniens: étude clinique et métabolique cérébrale par TEP au 18FDG - APO TEPL’objectif thérapeutique principal dans la maladie de Parkinson est de contrôler les fluctuations motrices. Cependant des fluctuations non motrices (FNM) sont fréquemment observées et semblent corrélées à la sévérité de la maladie. La stabilité dans le temps de l’efficacité du traitement dopaminergique est le moyen le plus pertinent pour améliorer les fluctuations tant motrices que non motrices.MedDRA version: 9.1 Level: LLT Classification code 10013113 Term: Disease Parkinson's
EUCTR2008-006045-10-FRCHU de Rennes30
已完成
不适用
Dopaminergic neurotransmission and cognitive deterioration in velocardiofacial syndrome
NL-OMON33641Medisch Universitair Ziekenhuis Maastricht44
REBOOT: Releasing the brakes on adult plasticity | 临床试验